Novo Nordisk A/S

(New York Stock Exchange)
Back to all articles
Somewhat Bearish -25

Novo Nordisk opens to New York listing while Novo Nordisk stock falls 1.10 percent

Analyst downgrade Company update Patent expiry AI-generated analysis

πŸ“‰ Novo Nordisk stock fell 1.10% to EUR 33.20 on October 1, 2026, trading below the prior close of EUR 33.57.

πŸš€ Q2 adjusted sales rose 7% year-over-year to DKK 78.49 billion, with obesity care sales surging 16%.

πŸ’° Adjusted operating profit increased 11% in the second quarter of 2026.

⚠️ Full-year 2026 outlook forecasts adjusted sales growth between 0% and a decline of up to 6% at constant exchange rates.

πŸ‡ΊπŸ‡Έ CEO Mike Doustdar indicated interest in replacing American depositary receipts with a direct New York listing to boost U.S. visibility.

πŸ“‰ Jefferies analyst cut the price target to DKK 275 and reduced the valuation multiple to 12.5x due to patent expiry risks.

πŸ“… Q3 2026 earnings are scheduled for release on November 3, 2026, serving as a key checkpoint for investors.

Bullish Signals
  • Novo Nordisk reported a 7% increase in adjusted sales to DKK 78.49 billion in Q2 2026.
  • Obesity care sales surged 16% in the second quarter, contributing significantly to overall revenue growth.
  • Adjusted operating profit grew by 11% during the second quarter of 2026.
Risk Factors
  • The company's full-year 2026 outlook projects adjusted sales growth between 0% and a decline of up to 6% due to pricing pressure.
  • Analyst Jefferies cut its price target to DKK 275 citing uncertainty surrounding semaglutide's patent expiry.
  • The stock fell 1.10% on October 1, 2026, reflecting investor caution regarding the mixed operating backdrop and competitive conditions.
Full Analysis
Novo Nordisk A/S is exploring a strategic shift to open its New York listing, potentially replacing American depositary receipts with direct shares to enhance its U.S. market profile. This move was discussed by CEO Mike Doustdar, though no final decision has been announced as of early October 2026. Financial performance for the second quarter of 2026 showed adjusted sales rising 7% to DKK 78.49 billion, driven by a 16% surge in obesity care sales and an 11% increase in operating profit. However, U.S. operations grew more modestly at 4%, reflecting mixed regional dynamics. Despite strong quarterly results, the company's full-year 2026 outlook remains cautious, projecting adjusted sales growth between 0% and a decline of up to 6% due to pricing pressures and intensifying competition. The stock fell 1.10% on October 1, 2026, as investors weighed these factors alongside upcoming Q3 earnings. Analyst sentiment is divided, with Jefferies cutting its price target to DKK 275 and reducing its valuation multiple amid concerns over patent expiry for semaglutide. Investors will watch the November 3, 2026 earnings release to determine if recent sales growth can sustain momentum through the year.